around.pk
Friday, 20 November 2026
☀ Karachi 25°⛅ Lahore 18°⛅ Islamabad 15°
Health

Daily Pill Shows Early Promise Against Hard-to-Treat Pancreatic Cancer

An experimental once-daily tablet, daraxonrasib, slowed or shrank tumours in a majority of patients with advanced pancreatic cancer in an early-stage trial, though doctors stress it is not yet a cure.

around.pk·just now

An experimental once-daily tablet has produced encouraging early results in patients with advanced pancreatic cancer, a disease that has long resisted effective treatment. In a Phase I/II clinical trial, the drug daraxonrasib was given alongside chemotherapy to 61 patients who had recently been diagnosed with pancreatic cancer that had already spread to other parts of the body.

According to the trial findings, tumours stopped growing in about 90 percent of participants, while more than 60 percent saw their tumours shrink or disappear. In roughly 8 percent of patients, or about one in 12, the cancer could no longer be detected on CT scans. Participants were followed for an average of 18 months, and some showed no sign of the disease returning during that period, although researchers caution that longer studies are needed to learn how long the treatment can keep the disease under control.

The drug works by targeting RAS mutations, genetic changes that drive tumour growth and are present in most pancreatic cancers. By blocking these mutations, the treatment cuts off a key mechanism the cancer uses to grow. Similar mutations appear in other cancers, including lung and ovarian cancer, suggesting the approach could be studied more widely. Cancer Research UK described the results as the biggest advance in pancreatic cancer treatment in decades, with its Dr Sam Godfrey saying the drug had found a way to target mutations previously considered very difficult to treat.

Dr Wungki Park of Memorial Sloan Kettering Cancer Center said the early findings showed higher tumour response rates, deeper responses and nearly twice the duration of disease control, which could eventually translate into longer survival for patients.

Doctors have stressed that the results do not mean the drug is a cure. Cancer can return even when scans show no detectable disease, and further research is needed to establish whether the treatment can produce lasting remission and improve overall survival.

Pancreatic cancer remains one of the hardest cancers to treat. It accounts for about 3 percent of all cancer cases in the United States but causes roughly 8 percent of cancer deaths, killing around 53,000 people each year. The findings add to a growing body of research into precision medicines that target the specific genetic drivers of tumours.

Memorial Sloan Kettering Cancer CenterCancer Research UKDaraxonrasibPancreatic cancerSam GodfreyWungki Park

Continue the story

View all →

Read more